Guardant Health (NASDAQ:GH) Releases Earnings Results, Beats Expectations By $0.46 EPS

Guardant Health (NASDAQ:GH) issued its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.46, FiscalAI reports. The company had revenue of $360.98 million during the quarter, compared to analysts’ expectations of $350.72 million. During the same quarter last year, the firm posted ($0.74) earnings per share. The firm’s quarterly revenue was up 36.1% on a year-over-year basis.

Here are the key takeaways from Guardant Health’s conference call:

• Revenue growth accelerated, and Guardant raised its 2026 outlook. Third-quarter revenue increased 36% to $361 million, prompting the company to raise full-year revenue guidance to $1.36 billion–$1.37 billion, or approximately 38%–40% growth.
• Shield screening showed strong adoption and expanding coverage. Shield volume rose 246% to 83,000 tests, while new payer decisions are expected to bring coverage to about 100 million people by 2027; management raised its full-year Shield volume and revenue outlook.
• Oncology growth was supported by rising test volumes and product milestones. Oncology volume increased 58%, with Reveal volumes more than doubling; Guardant also received FDA approval for ESR1 monitoring, submitted Guardant360 Tissue for FDA review, and expects to launch Reveal Ultra clinically before year-end.
• Cost improvements and lower cash burn supported the path toward profitability. Non-GAAP gross margin improved to 67%, Shield cost per test fell to $330—below the company’s year-end target—and adjusted EBITDA loss narrowed to $37 million; Guardant reiterated its goal of company-wide cash-flow breakeven by the end of 2027.
• Full-year free-cash-flow-burn guidance increased. Guardant now expects $205 million–$220 million of burn, partly because $10 million–$15 million in Guardant360 Liquid CDx payments are expected to shift into 2027 due to a CMS billing-system delay; the company also plans continued investment in commercial expansion.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $153.01 on Friday. The firm has a market capitalization of $20.53 billion, a PE ratio of -43.84 and a beta of 1.67. The firm’s 50-day moving average is $169.66 and its two-hundred day moving average is $131.82. Guardant Health has a 1 year low of $74.55 and a 1 year high of $191.05.

Insiders Place Their Bets

In related news, CEO Amirali Talasaz sold 37,500 shares of Guardant Health stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $169.16, for a total value of $6,343,500.00. Following the completion of the transaction, the chief executive officer owned 37,500 shares in the company, valued at approximately $6,343,500. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Terilyn Monroe sold 46,300 shares of Guardant Health stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the completion of the transaction, the insider owned 22,979 shares of the company’s stock, valued at $3,794,292.48. This trade represents a 66.83% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 163,060 shares of company stock valued at $27,538,217. 5.60% of the stock is owned by company insiders.

Guardant Health News Summary

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Q3 revenue rose 36% year over year to $361 million, exceeding the $350.7 million analyst estimate. Oncology revenue grew 25% to $231.3 million, while oncology test volume increased 58% to 117,000. The company also increased its 2026 revenue guidance, a positive signal for continued growth. Guardant Health Q3 2026 results and guidance
• Neutral Sentiment: Guardant reported a quarterly loss of $0.29 per share, compared with a $0.39 loss a year earlier. One report described the loss as in line with consensus, so the results’ clearest upside was revenue and test-volume growth rather than earnings. Zacks Q3 results
• Negative Sentiment: Despite the sales beat and higher guidance, reports said GH shares declined following the release as blood-testing stocks were under pressure. The reaction suggests investors may have been focused on sector weakness or expectations beyond the headline results. Report on GH’s post-earnings stock reaction Blood-testing stocks coverage

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on GH shares. Piper Sandler reiterated an “overweight” rating on shares of Guardant Health in a research report on Tuesday, September 15th. Stifel Nicolaus upped their price objective on shares of Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, July 31st. BTIG Research upped their price objective on shares of Guardant Health from $195.00 to $210.00 and gave the stock a “buy” rating in a report on Tuesday, October 27th. Stephens increased their price objective on shares of Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Finally, Barclays boosted their target price on Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and an average price target of $191.00.

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.